TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT06526923: A Phase 1/2 Trial of SP-101 for the Treatment of Cystic Fibrosis (CF)

Sponsor: Spirovant Sciences, Inc. · Phase: PHASE1/PHASE2 · Area: RARE_ORPHAN · Target Enrollment: 20 pts

Competing Trials Overlap

5 Active Trials

Excess Burn Exposure

$1,181,925

Rescue Site Savings

+$787,950

Unlock Full NCT06526923 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06526923 Rescue Dossier →